维德思投资 VRTS 深 沪
等待开盘 08-25 09:30:00 美东时间
168.40
+1.310
+0.78%
华盛通- 最 高169.6299
- 今 开167.77
- 成交量 9.67万股
- 最 低 167.02
- 昨 收 167.09
- 总市值 11.15亿
- 52周最高 194.01
- 市盈率 静 8.43
- 换手率 1.46%
- 52周最低 116.805
- 委 比 8.70%
- 总股本 662.27万
- 历史最高 300.00
- 量 比 1.13
- 振 幅 1.56%
- 历史最低 -4.51
- 每 手 1
- 风险率 18.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wall Street's Most Accurate Analysts Spotlight On 3 Financial Stocks With Over 5% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Benzinga readers can review the latest analyst takes on their favorite stocks by v...
08-24 19:50
Dividend Roundup: Home Depot, Sysco, 3M, T-Mobile, and more
This week's dividend activity included increased payouts from United Bancorp (UBCP) and Virtus Investment (VRTS) as well as declarations from Home Depot (HD) and Sysco (SYY). Additionally, looking tow...
08-21 20:49
Virtus Investment Partners preliminary July AUM declines to $148.9B
Virtus Investment Partners (VRTS) said on Wednesday that its preliminary AUM as of July 31 stood at $148.9B, while other fee-earning assets came in at $1.7B for total client assets of $150.6B. The fig...
08-12 20:51
美股大行评级 | 最高400美元！亚马逊绩后获11家大行上调目标价；苹果绩后评级分歧大！3家上调，3家下调；德康医疗、万事达、神经分泌生物科学获多家大行上调目标价
今日重点评级关注：TD Cowen：维持加拿大鹅"买入"评级，目标价从13美元升至18美元；瑞银：维持吉登运动服"买入"评级，目标价从110美元升至111美元
08-03 11:38
Barclays Maintains Underweight on Virtus Inv, Lowers Price Target to $135
Barclays analyst Benjamin Budish maintains Virtus Inv (NYSE:VRTS) with a Underweight and lowers the price target from $141 to $135.
07-31 20:28
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
美股大行评级 | 美银上调AMD目标价从550美元升至620美元；IBM暴跌25%！大摩上调目标价升至293美元，汇丰下调评级至"卖出"目标价降至191美元
今日重点评级关注：Keybanc：维持迈威尔科技"超配"评级，目标价从385美元升至400美元；丰业银行：维持科尔黛伦矿业"跑赢大市"评级，目标价从27.5美元升至28.5美元
07-15 10:22
Barclays Maintains Underweight on Virtus Inv, Raises Price Target to $141
Barclays analyst Benjamin Budish maintains Virtus Inv (NYSE:VRTS) with a Underweight and raises the price target from $125 to $141.
07-14 19:21
Virtus Investment Partners reports June-end AUM of $152.2B
Virtus Investment Partners (VRTS) on Monday reported preliminary assets under management of $152.2B as of June 30. Says change from March-end reflects market performance, positive ETF and wealth manag...
07-13 20:14
美股大行评级 | 潜在涨幅90.66%！Tango Therapeutics获杰富瑞升目标价至60美元，上调至"买入"评级
今日重点评级关注：杰富瑞：上调Tango Therapeutics评级至"买入"，目标价从27美元升至60美元；Susquehanna：维持安森美半导体"积极"评级，目标价从120美元升至140美元
06-29 15:49
